Skip to main content


Fig. 7 | Journal of Experimental & Clinical Cancer Research

Fig. 7

From: Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC

Fig. 7

Effect of osimertinib combined with pemetrexed or cisplatin on signaling transduction pathways and cell death regulators in PC9 and PC9T790M cell lines. PC9 and PC9T790M cells were treated with 50 nM osimertinib, 50 nM pemetrexed, 500 nM cisplatin or their combination and after 24 h (a) or 48 h following the schedules indicated in Fig. 4b (b) the cells were lysed and western blot analysis was performed to detect the indicated proteins. Results are representative of two independent experiments

Back to article page